BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31215546)

  • 1. [Selective α2-agonists in the treatment of glaucoma: pharmacology, efficacy and safety].
    Kurysheva NI
    Vestn Oftalmol; 2019; 135(2):144-150. PubMed ID: 31215546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Selective α2 agonists in the treatment of glaucoma: neuroprotective properties and impact on ocular blood flow].
    Kurysheva NI
    Vestn Oftalmol; 2019; 135(3):113-120. PubMed ID: 31393455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
    Greenfield DS; Liebmann JM; Ritch R
    J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
    Schuman JS
    Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of brimonidine in children with glaucoma.
    Enyedi LB; Freedman SF
    J AAPOS; 2001 Oct; 5(5):281-4. PubMed ID: 11641636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brimonidine.
    Bakheit AH; Alomar AM; Darwish H; Alkahtani HM
    Profiles Drug Subst Excip Relat Methodol; 2023; 48():1-37. PubMed ID: 37061271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brimonidine tartrate for the treatment of glaucoma.
    Oh DJ; Chen JL; Vajaranant TS; Dikopf MS
    Expert Opin Pharmacother; 2019 Jan; 20(1):115-122. PubMed ID: 30407890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
    LeBlanc RP
    Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The ocular hypotensive effect and safety of 0.2% brimonidine].
    Yu M; Li Y; Ge J
    Yan Ke Xue Bao; 2001 Dec; 17(4):235-8. PubMed ID: 12567513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic beta-blocker therapy and brimonidine and timolol.
    Coulibaly R
    Ophthalmology; 2001 Aug; 108(8):1368. PubMed ID: 11470677
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension [corrected].
    Carlsson AM; Chauhan BC; Lee AA; Leblanc RP
    Am J Ophthalmol; 1999 Dec; 128(6):697-701. PubMed ID: 10612505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma.
    Wheeler LA; Woldemussie E
    Eur J Ophthalmol; 2001; 11 Suppl 2():S30-5. PubMed ID: 11592528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.
    Katz LJ
    Am J Ophthalmol; 1999 Jan; 127(1):20-6. PubMed ID: 9932994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
    Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
    Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brimonidine for glaucoma.
    Rahman MQ; Ramaesh K; Montgomery DM
    Expert Opin Drug Saf; 2010 May; 9(3):483-91. PubMed ID: 20367525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma.
    Yüksel N; Altintaş O; Karabaş L; Alp B; Cağlar Y
    Ophthalmologica; 1999; 213(4):228-33. PubMed ID: 10420106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological profile and clinical efficacy of brimonidine tartrate (AIPHAGAN(®) ophthalmic solution 0.1%)].
    Kaneko E; Wada T; Minagawa Y; Inoue Y
    Nihon Yakurigaku Zasshi; 2012 Oct; 140(4):177-82. PubMed ID: 23059902
    [No Abstract]   [Full Text] [Related]  

  • 18. Preclinical evaluation of brimonidine.
    Burke J; Schwartz M
    Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S9-18. PubMed ID: 8970245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anterior uveitis as a side effect of topical brimonidine.
    Byles DB; Frith P; Salmon JF
    Am J Ophthalmol; 2000 Sep; 130(3):287-91. PubMed ID: 11020406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy.
    thoe Schwartzenberg GW; Buys YM
    Ophthalmology; 1999 Aug; 106(8):1616-20. PubMed ID: 10442912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.